Oct 16, 2024
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
Oct 09, 2024
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)
Oct 08, 2024
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
Sep 18, 2024
Viatris Announces the Pricing Terms of Maximum Tender Offer
Sep 17, 2024
Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer
Sep 10, 2024
Viatris Announces Expiration and Results of Any and All Cash Tender Offers
Sep 04, 2024
Viatris Announces Cash Tender Offers for Certain Outstanding Notes
Aug 23, 2024
Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress
Aug 06, 2024
Viatris Announces Second Quarter 2024 Dividend
Jul 03, 2024
Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture
Jul 02, 2024
U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
Jun 25, 2024
Viatris Named to TIME's World's Most Sustainable Companies 2024 List
Jun 07, 2024
Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024
Jun 03, 2024
Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors
May 31, 2024
Viatris to Participate in the Jeffries Global Healthcare Conference
May 21, 2024
Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale
May 09, 2024
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
May 02, 2024
Viatris to Participate in the BofA Securities 2024 Health Care Conference
May 01, 2024
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
Apr 16, 2024
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024